- The Wall Street Journal•3 days ago
Perrigo Co.’s credit outlook could come under pressure as the pharmaceutical company delays filing its 10-K annual report, according to Moody’s Investors Service.
- Moody's•3 days ago
Announcement: Moody's: Perrigo's delayed 10- K filing is credit negative. Global Credit Research- 20 Mar 2017. New York, March 20, 2017-- Moody's Investors Service commented that On Thursday, March 16, ...
- PR Newswire•7 days ago
Perrigo and E&Y have not been able to fully complete their respective reviews of the historical revenue recognition practices associated with the Tysabri® royalty stream by the Form 10-K filing due date under the extension provided by Rule 12b-25 of the Securities Exchange Act of 1934. Any effects related to the final conclusion of these technical accounting matters are not expected to have a material impact on the Company's historical cash flow or future net cash flow. The Company continues to expect to close the sale of the Tysabri® royalty stream to RPI Finance Trust, an affiliate of Royalty Pharma, within the next ten days.
PRGO : Summary for Perrigo Company plc Ordinary Sh - Yahoo Finance
Perrigo Company plc (PRGO)
NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
|Day's Range||67.36 - 68.75|
|52 Week Range||67.08 - 133.53|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||-6.79|
|Dividend & Yield||0.64 (0.94%)|
|1y Target Est||N/A|